{"denoms":[{"counts":[{"groupId":"BG000","value":"23"}],"units":"Participants"}],"groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"BG000","title":"Ixabepilone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.1","value":"55.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"40-49 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"50-59 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"60-69 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"Leiomyosarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Carcinosarcoma, malignant mixed Mullerian tumor"}],"paramType":"NUMBER","title":"Histologic Type","unitOfMeasure":"participants"}],"populationDescription":"Eligible and treated patients"}